Efficacy of monoclonal antibodies against defined antigens for passive immunotherapy of chronic gastrointestinal cryptosporidiosis

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 2, 2002, Pages 275-282

  Riggs, Michael W ^a   Schaefer, Deborah A ^a   Kapil, Sushila J ^a   Barley Maloney, Lise ^a   Perryman, Lance E ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3E2; MONOCLONAL ANTIBODY 3H2; MONOCLONAL ANTOBODY 1E10; UNCLASSIFIED DRUG;

ARTICLE; BIOREACTOR; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DRUG EFFICACY; DRUG FORMULATION; DRUG TARGETING; FEMALE; IMMUNOTHERAPY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOREACTORS; BODY WEIGHT; CHRONIC DISEASE; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DISEASE MODELS, ANIMAL; FECES; FEMALE; GASTROINTESTINAL DISEASES; IMMUNIZATION, PASSIVE; MICE; MICE, SCID; OOCYTES; TREATMENT OUTCOME;

EID: 0036150241     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.2.275-282.2002     Document Type: Article

References (83)

1. Differential intraepithelial lymphocyte phenotypes following Cryptosporidium parvum challenge in susceptible and resistant athymic strains of mice
2. Adoptive transfer of immunity with intraepithelial lymphocytes in Cryptosporidium parvum-infected severe combined immunodeficient mice
3. Effects of immune colostrum and orally administered antisporozoite monoclonal antibodies on the outcome of Cryptosporidium parvum infections in neonatal mice
4. Immunofluorescent microscopic visualization of trails left by gliding Cryptosporidium parvum sporozoites
5. Cellular invasion by avian Eimeria species
6. Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa peritonitis in a murine model
7. A novel multi-domain mucin-like glycoprotein of Cryptosporidium parvum mediates invasion
8. Synthesis and evaluation of dinitroanilines for treatment of cryptosporidiosis
9. Monoclonal antibody immunotherapy in nude mice persistently infected with Cryptosporidium parvum
10. Cryptosporidium parvum merozoites share neutralization-sensitive epitopes with sporozoites
11. Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide, and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model
12. Prophylaxis and chemotherapy: Human and animal
13. A 23-kDa recombinant antigen of Cryptosporidium parvum induces a cellular immune response on in vitro stimulated spleen and mesenteric lymph node cells from infected mice
14. Designing blood-stage vaccines against Babesia bovis and Babesia bigemina
15. Sequential protein secretion from three distinct organelles of Toxoplasma gondii accompanies invasion of human fibroblasts
16. Passive antibody therapies: Progress and continuing challenges
17. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies
18. Mediation of Cryptosporidium parvum infection in vitro by mucin-like glycoproteins defined by a neutralizing monoclonal antibody
19. Molecular cloning and expression of a gene encoding Cryptosporidium parvum glycoproteins gp40 and gp15
20. Gamma interferon functions in resistance to Cryptosporidium parvum infection in severe combined immunodeficient mice
21. Mechanisms of attachment and internalization of Cryptosporidium parvum to biliary and intestinal epithelial cells
22. Biochemical peculiarities and drug targets in Cryptosporidium parvum: Lessons from other coccidian parasites
23. Adhesive proteins of the malaria parasite
24. Antibody-based immunotherapy of cryptosporidiosis
25. Apical organelles and host-cell invasion by Apicomplexa
26. Antimicrobial combinations
27. Role of immunoglobulin A monoclonal antibodies against P23 in controlling murine Cryptosporidium parvum infection
28. Immunotherapeutic efficacy of bovine colostral immunoglobulins from a hyperimmunized cow against cryptosporidiosis in neonatal mice
29. Hyperimmune bovine colostrum neutralizes Cryptosporidium sporozoites and protects mice against oocyst challenge
30. The general biology of Cryptosporidium
31. Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic Escherichia coli
32. Paromomycin and geneticin inhibit intracellular Cryptosporidium parvum without trafficking through the host cell cytoplasm: Implications for drug delivery
33. The gamma interferon gene knockout mouse: A highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvum
34. Attachment of Cryptosporidium parvum sporozoites to MDCK cells in vitro
35. Enteric lesions and diarrhea in gnotobiotic calves monoinfected with Crytosporidium species
36. Hyperimmune bovine colostrum specific for recombinant Cryptosporidium parvum antigen confers partial protection against cryptosporidiosis in immunosuppressed adult mice
37. Attachment of Cryptosporidium parvum sporozoites to human intestinal epithelial cells
38. Interaction of antigens and antibodies at mucosal surfaces
39. Cryptosporidium parvum apical complex glycoprotein CSL contains a sporozoite ligand for intestinal epithelial cells
40. Characterization of an intestinal epithelial cell receptor recognized by the Cryptosporidium parvum sporozoite ligand CSL
41. Laboratory models of cryptosporidiosis
42. Ultrastructure of the attachment of Cryptosporidium sporozoites to tissue culture cells
43. Effect of antibodies to recombinant and synthetic peptides on P. falciparum sporozoites in vitro
44. Antigens of Cryptosporidium sporozoites recognized by immune sera of infected animals and humans
45. Toxoplasma gondii: A monoclonal antibody that inhibits intracellular replication
46. The thrombospondin-related protein family of apicomplexan parasites: The gears of the cell invasion machinery
47. Receptor/ligand interactions between Cryptosporidium parvum and the surface of the host cell
48. Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients
49. Dual action of anti-sporozoite antibodies in vitro
50. Prophylactic effect of bovine anti-Cryptosporidium hyperimmune colostrum immunoglobulin in healthy volunteers challenged with Cryptosporidium parvum
51. CpABC, a Cryptosporidium parvum ATP-binding cassette protein at the host-parasite boundary in intracellular stages
52. A cloned gene of Cryptosporidium parvum encodes neutralization-sensitive epitopes
53. Protection of calves against cryptosporidiosis with immune bovine colostrum induced by a Cryptosporidium parvum recombinant protein
54. Effect of orally administered monoclonal antibody on persistent Cryptosporidium parvum infection in scid mice
55. Kinetics of Cryptosporidium parvum sporozoite neutralization by monoclonal antibodies, immune bovine serum, and immune bovine colostrum
56. r Cryptosporidium parvum sporozoite glycoprotein recognized by protective hyperimmune bovine colostral immunoglobulin
57. Ultrastructure, fractionation and biochemical analysis of Cryptosporidium parvum sporozoites
58. Cloning of the immunodominant 17-kDa antigen from Cryptosporidium parvum
59. Immunology: Host response and development of passive immunotherapy and vaccines
60. Bovine antibody against Cryptosporidium parvum elicits a circumsporozoite precipitate-like reaction and has immunotherapeutic effect against persistent cryptosporidiosis in SCID mice
61. Neutralization-sensitive epitopes are exposed on the surface of infectious Cryptosporidium parvum sporozoites
62. Cryptosporidium parvum sporozoite pellicle antigen recognized by a neutralizing monoclonal antibody is a β-mannosylated glycolipid
63. Infectivity and neutralization of Cryptosporidium parvum sporozoites
64. Protective monoclonal antibody defines a circumsporozoite-like glycoprotein exoantigen of Cryptosporidium parvum sporozoites and merozoites
65. Evidence for the shikimate pathway in apicomplexan parasites
66. Protection of kids against Cryptosporidium parvum infection after immunization of dams with CP15-DNA
67. Characterization and formulation of multiple epitope-specific neutralizing monoclonal antibodies for passive immunization against cryptosporidiosis
68. Malaria sporozoites release circumsporozoite protein from their apical end and translocate it along their surface
69. Cloning and sequence analysis of a highly polymorphic Cryptosporidium parvum gene encoding a 60-kilodalton glycoprotein and characterization of its 15- and 45-kilodalton zoite surface antigen products
70. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge
71. Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli
72. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models
73. Profiles of healing and nonhealing Cryptosporidium parvum infection in C57BL/6 mice with functional B and T lymphocytes: The extent of gamma interferon modulation determines the outcome of infection
74. Identification of a 15-kilodalton surface glycoprotein on sporozoites of Cryptosporidium parvum
75. Cryptosporidiosis: Laboratory investigations and chemotherapy
76. Evaluation of an animal model system for cryptosporidiosis: Therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin
77. Chronic cryptosporidial diarrhoea and hyperimmune cow colostrum
78. Cessation of Cryptosporidium-associated diarrhea in an acquired immunodeficiency syndrome patient after treatment with hyperimmune bovine colostrum
79. An in vitro model of infection of human biliary epithelial cells by Cryptosporidium parvum
80. Cryptosporidium: Molecular basis of host-parasite interaction
81. 12N]bis(Ethyl)-cis-6,7-dehydrospermine: A new drug for treatment and prevention of Cryptosporidium parvum infection of mice deficient in T-cell receptor alpha
82. Preventing infectious disease with passive immunization
83. Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases